Elite Pharmaceuticals Inc (ELTP)
0.5101
+0.01
(+1.75%)
USD |
OTCM |
Nov 04, 15:59
Elite Pharmaceuticals Max Drawdown (5Y): 87.94% for Sept. 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2024 | 87.94% |
| August 31, 2024 | 87.94% |
| July 31, 2024 | 87.94% |
| June 30, 2024 | 87.94% |
| May 31, 2024 | 89.83% |
| April 30, 2024 | 89.83% |
| March 31, 2024 | 90.10% |
| February 29, 2024 | 90.10% |
| January 31, 2024 | 90.10% |
| December 31, 2023 | 90.10% |
| November 30, 2023 | 90.10% |
| October 31, 2023 | 90.50% |
| September 30, 2023 | 92.16% |
| August 31, 2023 | 92.16% |
| July 31, 2023 | 92.16% |
| June 30, 2023 | 92.16% |
| May 31, 2023 | 92.16% |
| April 30, 2023 | 92.16% |
| March 31, 2023 | 92.16% |
| February 28, 2023 | 92.16% |
| January 31, 2023 | 92.16% |
| December 31, 2022 | 92.16% |
| November 30, 2022 | 92.16% |
| October 31, 2022 | 92.16% |
| September 30, 2022 | 92.16% |
| Date | Value |
|---|---|
| August 31, 2022 | 92.16% |
| July 31, 2022 | 92.16% |
| June 30, 2022 | 92.16% |
| May 31, 2022 | 92.16% |
| April 30, 2022 | 92.16% |
| March 31, 2022 | 92.16% |
| February 28, 2022 | 92.16% |
| January 31, 2022 | 92.16% |
| December 31, 2021 | 92.16% |
| November 30, 2021 | 92.16% |
| October 31, 2021 | 92.16% |
| September 30, 2021 | 92.16% |
| August 31, 2021 | 92.16% |
| July 31, 2021 | 92.16% |
| June 30, 2021 | 92.16% |
| May 31, 2021 | 92.16% |
| April 30, 2021 | 92.16% |
| March 31, 2021 | 92.16% |
| February 28, 2021 | 92.16% |
| January 31, 2021 | 92.16% |
| December 31, 2020 | 92.16% |
| November 30, 2020 | 92.16% |
| October 31, 2020 | 92.16% |
| September 30, 2020 | 92.16% |
| August 31, 2020 | 92.16% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
87.94%
Minimum
Jun 2024
92.16%
Maximum
Nov 2019
91.59%
Average
92.16%
Median
Nov 2019
Max Drawdown (5Y) Benchmarks
| Biomarin Pharmaceutical Inc | 52.14% |
| BioCardia Inc | 98.49% |
| Zevra Therapeutics Inc | 99.27% |
| Verrica Pharmaceuticals Inc | 93.64% |
| Terns Pharmaceuticals Inc | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 30.45 |
| Beta (5Y) | 0.1827 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 82.10% |
| Historical Sharpe Ratio (5Y) | 0.4013 |
| Historical Sortino (5Y) | 1.375 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 19.19% |